AU2001282364A1 - Diagnosis and treatment of prostate cancer - Google Patents

Diagnosis and treatment of prostate cancer

Info

Publication number
AU2001282364A1
AU2001282364A1 AU2001282364A AU8236401A AU2001282364A1 AU 2001282364 A1 AU2001282364 A1 AU 2001282364A1 AU 2001282364 A AU2001282364 A AU 2001282364A AU 8236401 A AU8236401 A AU 8236401A AU 2001282364 A1 AU2001282364 A1 AU 2001282364A1
Authority
AU
Australia
Prior art keywords
hne
gated
voltage
nucleic acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282364A
Inventor
James Kenneth Joseph Diss
Mustafa Bilgin Ali Djamgoz
Scott Paton Fraser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of AU2001282364A1 publication Critical patent/AU2001282364A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of diagnosing cancer in a human patient comprising the steps of (i) obtaining a sample containing nucleic acid and/or protein from the patient; and (ii) determining whether the sample contains a level of hNe—Na voltage-gated Na+ channel nucleic acid or protein associated with cancer. A method of treating cancer comprising the step of administering to the patient an agent which selectively prevents the function of hNe—Na voltage-gated Na+ channel. A genetic construct comprising a nucleic acid encoding a molecule capable of preventing the function of hNe—Na voltage-gated Na+ channel expressed in a cell. The methods and compositions are particularly suited to prostate cancer.
AU2001282364A 2000-09-02 2001-09-03 Diagnosis and treatment of prostate cancer Abandoned AU2001282364A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0021617.6A GB0021617D0 (en) 2000-09-02 2000-09-02 Diagnosis and treatment of cancer
GB0021617.6 2000-09-02
PCT/GB2001/003940 WO2002018637A2 (en) 2000-09-02 2001-09-03 Diagnosis and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
AU2001282364A1 true AU2001282364A1 (en) 2002-03-13

Family

ID=9898761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282364A Abandoned AU2001282364A1 (en) 2000-09-02 2001-09-03 Diagnosis and treatment of prostate cancer

Country Status (10)

Country Link
US (2) US20060166194A1 (en)
EP (1) EP1313882B1 (en)
JP (1) JP2004507254A (en)
AT (1) ATE361993T1 (en)
AU (1) AU2001282364A1 (en)
CY (1) CY1107715T1 (en)
DE (1) DE60128368T2 (en)
ES (1) ES2288979T3 (en)
GB (1) GB0021617D0 (en)
WO (1) WO2002018637A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002084284A2 (en) * 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer:ii
US7393657B2 (en) 2001-04-12 2008-07-01 Imperial College Innovations Limited Diagnosis and treatment of cancer: I
US7670771B2 (en) * 2004-01-21 2010-03-02 University Of Utah Research Foundation Mutant sodium channel Nav1.7 nucleic acid methods
AU2005249492B2 (en) * 2004-05-27 2011-09-22 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20080070792A1 (en) 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
WO2009067429A1 (en) * 2007-11-19 2009-05-28 Genentech, Inc. Compositions and methods for inhibiting tumor progression
GB0811360D0 (en) * 2008-06-20 2008-07-30 Imp Innovations Ltd Methods
PT2334812T (en) 2008-09-20 2017-03-29 Univ Leland Stanford Junior Noninvasive diagnosis of fetal aneuploidy by sequencing
US20120283116A1 (en) 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
JP2021527437A (en) * 2018-06-22 2021-10-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Oligonucleotides for regulating SCN9A expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789575B8 (en) * 1994-11-02 2009-01-14 Allelix Neuroscience, Inc. Peripheral nervous system specific sodium channels, dna encoding therefor, drug screening, and methods of making and using thereof
US7312043B2 (en) * 2000-07-10 2007-12-25 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods

Also Published As

Publication number Publication date
US20080145859A1 (en) 2008-06-19
DE60128368T2 (en) 2008-01-10
WO2002018637A2 (en) 2002-03-07
ATE361993T1 (en) 2007-06-15
ES2288979T3 (en) 2008-02-01
WO2002018637A3 (en) 2002-11-21
GB0021617D0 (en) 2000-10-18
EP1313882B1 (en) 2007-05-09
US7759078B2 (en) 2010-07-20
JP2004507254A (en) 2004-03-11
US20060166194A1 (en) 2006-07-27
EP1313882A2 (en) 2003-05-28
DE60128368D1 (en) 2007-06-21
CY1107715T1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
CY1107715T1 (en) Diagnosis And Treatment Of Prostate Cancer
WO2002083945A3 (en) Diagnosis and treatment of cancer: i
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA02000192A (en) Compositions and methods for the therapy and diagnosis of lung cancer.
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001096388A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1870466A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
TR200103560T2 (en) Compositions for the diagnosis and treatment of breast cancer and their use
EP1767636A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
MXPA04000080A (en) Diagnostic and screening methods for bladder cancer.
ATE464391T1 (en) HYALURONIDASE FROM HUMAN PLASMA
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU7868300A (en) Prostate cancer marker proteins
WO2000009754A3 (en) HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
WO2001051513A3 (en) Ovarian tumor-associated sequences
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
WO2000008157A3 (en) Human anion transporter genes atnov
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer